Abstract
Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood, an autoimmune T-cell response to a melanocyte-associated antigen is considered to be a cause of VKH disease. The complex immunological response to interferon and ribavirin may induce or exacerbate the autoimmune condition; however, VKH disease is a very rare complication associated with interferon therapy in chronic hepatitis C. We report a case of VKH disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.
MeSH terms
-
Anti-Inflammatory Agents / therapeutic use
-
Antiviral Agents / adverse effects*
-
Antiviral Agents / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Fluorescein Angiography
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / adverse effects*
-
Interferon-alpha / therapeutic use
-
Magnetic Resonance Imaging
-
Middle Aged
-
Polyethylene Glycols / adverse effects*
-
Polyethylene Glycols / therapeutic use
-
Prednisolone / therapeutic use
-
Recombinant Proteins
-
Ribavirin / adverse effects*
-
Ribavirin / therapeutic use
-
Tomography, X-Ray Computed
-
Uveomeningoencephalitic Syndrome / diagnosis*
-
Uveomeningoencephalitic Syndrome / drug therapy
-
Uveomeningoencephalitic Syndrome / etiology
Substances
-
Anti-Inflammatory Agents
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
Prednisolone
-
peginterferon alfa-2b